Stampidine: A selective oculo-genital microbicide

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 1, 2005, Pages 10-19

  D'Cruz, Osmond J ^a,b   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

^b Paradigm Pharmaceuticals   (United States)

Author keywords

Adenovirus; Conjunctivitis; Contact lens; d4T; Eye infections; HIV AIDS; Stavudine

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAMPIDINE; STAVUDINE; UNCLASSIFIED DRUG; VIRUS RECEPTOR; ZALCITABINE; ZIDOVUDINE; ADENOVIRUS RECEPTOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; THYMIDINE PHOSPHATE;

ADENOVIRUS; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CONJUNCTIVITIS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG TOLERABILITY; EYE INFECTION; GENITAL TRACT INFECTION; GENITAL ULCER; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; REVIEW; TOXICITY TESTING; URETHRITIS; VIRUS STRAIN; ANIMAL; CLASSIFICATION; DRUG EFFECT; GENITAL SYSTEM; SEROTYPING; SOLUBILITY; VIRAL EYE INFECTION; VIROLOGY;

ADENOVIRIDAE; ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG STABILITY; EYE INFECTIONS, VIRAL; GENITALIA; HUMANS; RECEPTORS, VIRUS; SEROTYPING; SOLUBILITY; STAVUDINE; THYMIDINE MONOPHOSPHATE; URETHRITIS;

EID: 24044498347     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki168     Document Type: Review

References (111)

1. Ford E, Nelson KE, Warren D. Epidemiology of epidemic keratoconjunctivitis. [i#Epidemiol Rev#1i] 1987; [b#9#1b]: 244-61.
2. Warren D, Nelson KE, Farrar JA [i#et al.#1i] A large outbreak of epidemic keratoconjunctivitis: Problems in controlling nosocomial spread. [i#J Infect Dis#1i] 1989; [b#160#1b]: 938-43.
3. McMinn PC, Stewart J, Burrell CJ. A community outbreak of epidemic keratoconjunctivitis in central Australia due to adenovirus type 8. [i#J Infect Dis#1i] 1991; [b#164#1b]: 1113-8.
4. Takeuchi S, Itoh N, Uchio E [i#et al.#1i] Adenovirus strains of subgenus D associated with nosocomial infection as new etiological agents of epidemic keratoconjunctivitis in Japan. [i#J Clin Microbiol#1i] 1999; [b#37#1b]: 3392-4.
5. Chang CH, Lin KH, Sheu MM [i#et al.#1i] The change of etiological agents and clinical signs of epidemic viral conjunctivitis over an 18-year period in southern Taiwan. [i#Graefes Arch Clin Exp Ophthalmol#1i] 2003; [b#241#1b]: 554-60.
6. D'Angelo LJ, Hierholzer JC, Keenlyside RA [i#et al.#1i] Pharyngoconjunctival fever caused by adenovirus type 4: Report of a swimming pool-related outbreak with recovery of virus from pool water. [i#J Infect Dis#1i] 1979; [b#140#1b]: 42-7.
7. Uchio E, Matsuura N, Takeuchi S [i#et al.#1i] Acute follicular conjunctivitis caused by adenovirus type 34. [i#Am J Ophthalmol#1i] 1999; [b#128#1b]: 680-6.
8. Darougar S, Quinlan MP, Gibson JA [i#et al.#1i] Epidemic keratoconjunctivitis and chronic papillary conjunctivitis in London due to adenovirus type 19. [i#Br J Ophthalmol#1i] 1977; [b#61#1b]: 76-85.
9. Martone WJ, Hierholzer JC, Keenlyside RA [i#et al.#1i] An outbreak of adenovirus type 3 disease at a private recreation center swimming pool. [i#Am J Epidemiol#1i] 1980; [b#111#1b]: 229-37.
10. Mueller AJ, Klauss V. Main sources of infection in 145 cases of epidemic keratoconjunctivitis. [i#Ger J Ophthalmol#1i] 1993; [b#2#1b]: 224-7.
11. Jernigan JA, Lowry BS, Hayden FG [i#et al.#1i] Adenovirus type 8 epidemic keratoconjunctivitis in an eye clinic: Risk factors and control. [i#J Infect Dis#1i] 1993; [b#167#1b]: 1307-13.
12. Chhabra BK. Nosocomial transmission of epidemic keratoconjunctivitis to food handlers in a nursing home. [i#J Am Geriatr Soc#1i] 1995; [b#43#1b]: 1392-3.
13. Koo D, Bouvier B, Wesley M [i#et al.#1i] Epidemic keratoconjunctivitis in a university medical center ophthalmology clinic; need for re-evaluation of the design and disinfection of instruments. [i#Infect Control Hosp Epidemiol#1i] 1989; [b#10#1b]: 547-52.
14. Azar MJ, Dhaliwal DK, Bower KS [i#et al.#1i] Possible consequences of shaking hands with your patients with epidemic keratoconjunctivitis. [i#Am J Ophthalmol#1i] 1996; [b#121#1b]: 711-2.
15. Harley D, Harrower B, Lyon M [i#et al.#1i] A primary school outbreak of pharyngoconjunctival fever caused by adenovirus type 3. [i#Commun Dis Intell#1i] 2001; [b#25#1b]: 9-12.
16. Chaberny IE, Schnitzler P, Geiss HK [i#et al.#1i] An outbreak of epidemic keratoconjunctivitis in a pediatric unit due to adenovirus type 8. [i#Infect Control Hosp Epidemiol#1i] 2003; [b#24#1b]: 514-9.
17. Nauheim RC, Romanowski EG, Araullo-Cruz T [i#et al.#1i] Prolonged recoverability of desiccated adenovirus type 19 from various surfaces. [i#Ophthalmology#1i] 1990; [b#97#1b]: 1450-3.
18. Kowalski RP, Romanowski EG, Waikhom B [i#et al.#1i] The survival of adenovirus in multidose bottles of topical fluorescein. [i#Am J Ophthalmol#1i] 1998; [b#126#1b]: 835-6.
19. Gordon YJ, Gordon RY, Romanowski E [i#et al.#1i] Prolonged recovery of desiccated adenoviral serotypes 5, 8, and 19 from plastic and metal surfaces in vitro. [i#Ophthalmology#1i] 1993; [b#100#1b]: 1835-9.
20. Croes K. Contact lens market: Higher-value products, favorable demographics and international expansion create an accelerating growth industry. [i#OptiStock Optical Sector Report October 2003#1i]. http://www.optistock.com/mw/2003_10all.htm (15 April 2005, date last accessed).
21. Mah-Sadorra JH, Yavuz SG, Najjar DM [i#et al.#1i] Trends in contact lens-related corneal ulcers. [i#Cornea#1i] 2005; [b#24#1b]: 51-8.
22. Pepose JS. Contact lens disinfection to prevent transmission of viral disease. [i#CLAO J#1i] 1988; [b#14#1b]: 165-8.
23. Gordon JS, Aoki K, Kinchington PR. Adenovirus keratoconjunctivitis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. [i#Ocular Infection & Immunity#1i] St Louis, MO, USA: Mosby, 1996; 877-94.
24. Wadell G. Molecular epidemiology of human adenoviruses. [i#Curr Top Microbiol Immunol#1i] 1984; [b#110#1b]: 191-220.
25. Horwitz MS. Adenoviruses. In: Fields BN, Knipe DM, eds. [i#Virology#1i] 2nd edn. New York, NY, USA: Raven Press, 1990; 1723-40.
26. Shenk T. Adenoviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. [i#Fields Virology#1i] 3rd edn. Philadelphia, PA, USA: Lippincott-Raven Publishers, 1996; 2111-48.
27. Jawetz EA, Kimura A, Nicholas N [i#et al.#1i] New type of APC virus from keratoconjunctivitis. [i#Science#1i] 1955; [b#122#1b]: 1190-2.
28. Aoki K, Tagawa Y. A twenty-one year surveillance of adenoviral conjunctivitis in Sapporo, Japan. [i#Int Ophthalmol Clin#1i] 2002; [b#42#1b] 49-54.
29. Gordon JS. Adenovirus and other non-herpetic viral diseases. In: Smolin G, Thoft RA, eds. [i#The Cornea#1i] 3rd edn. New York, NY, USA: Little, Brown and Company, 1994; 215-22.
30. Darourgor S, Walpita P, Thaker U [i#et al.#1i] Adenovirus serotypes isolated from ocular infections in London. [i#Br J Ophthalmol#1i] 1983; [b#67#1b]: 111-4.
31. Kinchington PR, Turse SE, Kowalski RP [i#et al.#1i] Use of polymerase chain amplification reaction for the detection of adenoviruses in ocular swab specimens. [i#Invest Ophthalmol Vis Sci#1i] 1994; [b#35#1b]: 4126-34.
32. Corsaro D, Gut JP, Venard V [i#et al.#1i] Molecular epidemiology of ocular isolates of adenovirus 8 obtained over nine years. [i#J Clin Pathol#1i] 1999; [b#52#1b]: 860-1.
33. Chang CH, Sheu MM, Lin KH [i#et al.#1i] Hemorrhagic viral keratoconjunctivitis in Taiwan caused by adenovirus types 19 and 37: applicability of polymerase chain reaction-restriction fragment length polymorphism in detecting adenovirus genotypes. [i#Cornea#1i] 2001; [b#20#1b] 295-300.
34. Pring-Akerblom P, Adrian T. Characterization of adenovirus subgenus D fiber genes. [i#Virology#1i] 1995; [b#206#1b]: 564-71.
35. O'Donnell B, McCruden EA, Desselberger U. Molecular epidemiology of adenovirus conjunctivitis in Glasgow 1981-1991. [i#Eye#1i] 1993; [b#7#1b]: 8-14.
36. Harley D, Narrower B, Lyon M [i#et al.#1i] A primary school outbreak of pharyngoconjunctival fever caused by adenovirus type 3. [i#Commun Dis Intell#1i] 2001; [b#25#1b]: 9-12.
37. Harnett GB, Newnham WA. Isolation of adenovirus type 19 from the male and female genital tracts. [i#Br J Vener Dis#1i] 1981; [b#57#1b]: 55-7.
38. Swenson PD, Lowens MS, Celum CL [i#et al.#1i] Adenovirus types 2, 8, and 37 associated with genital infections in patients attending a sexually transmitted disease clinic. [i#J Clin Microbiol#1i] 1995; [b#33#1b]: 2728-31.
39. Cevenini R, Donati M, Landini MP [i#et al.#1i] Adenoviruses associated with an oculo-genital infection. [i#Microbiologica#1i] 1979; [b#2#1b]: 425-7.
40. Harnett GB, Phillips PA, Gollow MM. Association of genital adenovirus infection with urethritis in men. [i#Med J Aust#1i] 1984; [b#141#1b]: 337-8.
41. Laverty CR, Russell P, Black J [i#et al.#1i] Adenovirus infection of the cervix. [i#Acta Cytol#1i] 1977; [b#21#1b]: 114-7.
42. Phillips PA, Harnett GB, Gollow MM. Adenovirus type 19 and a closely related new serotype in genital infection. [i#Br J Vener Dis#1i] 1982; [b#58#1b]: 131-2.
43. Arnberg N, Pring-Akerblom P, Wadell G. Adenovirus type 37 uses sialic acid as a cellular receptor on Chang C cells. [i#J Virol#1i] 2002; [b#76#1b] 8834-41.
44. Arnberg N, Mei Y, Wadell G. Fiber genes of adenoviruses with tropism for the eye and the genital tract. [i#Virology#1i] 1997; [b#227#1b]: 239-44.
45. Hierholzer JC, Wigand R, Anderson LJ [i#et al.#1i] Adenoviruses from patients with AIDS: A plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47). [i#J Infect Dis#1i] 1988; [b#158#1b]: 804-13.
46. Green WR, Greaves WL, Frederick WR [i#et al.#1i] Renal infection due to adenovirus in a patient with human immunodeficiency virus infection. [i#Clin Infect Dis#1i] 1994; [b#18#1b]: 989-91.
47. Khoo SH, Bailey AS, de Jong JC [i#et al.#1i] Adenovirus infections in human immunodeficiency virus-positive patients: Clinical features and molecular epidemiology. [i#J Infect Dis#1i] 1995; [b#172#1b]: 629-37.
48. Carrigan DR. Adenovirus infections in immunocompromised patients. [i#Am J Med#1i] 1997; [b#102#1b]: 71-4.
49. De Jong JC, Wermenbol AG, Verweij-Uijterwaal MW [i#et al.#1i] Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. [i#J Clin Microbiol#1i] 1999; [b#37#1b]: 3940-5.
50. Sabin CA, Clewley GS, Deayton JR [i#et al.#1i] Shorter survival in HIV-positive patients with diarrhoea who excrete adenovirus from the GI tract. [i#J Med Virol#1i] 1999; [b#58#1b], 280-5.
51. Koopmann J, Dombrowski F, Rockstroh JK [i#et al.#1i] Fatal pneumonia in an AIDS patient coinfected with adenovirus and [i#Pneumocystis carinii. Infection#1i] 2000; [b#28#1b]: 323-5.
52. Kojaoghlanian T, Flomenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. [i#Rev Med Virol#1i] 2003; [b#13#1b] 155-71.
53. Perricone MA, Morris JE, Pavelka K [i#et al.#1i] Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. [i#Hum Gene Ther#1i] 2001; [b#12#1b]:1383-94.
54. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adeno-associated virus type 2 vectors. [i#Hum Gene Ther#1i] 2002; [b#13#1b] 1935-43.
55. Galanis E, Okuno SH, Nascimento AG [i#et al.#1i] Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. [i#Gene Ther#1i] 2005; [b#12#1b]: 437-45.
56. Sangro B, Mazzolini G, Ruiz J [i#et al.#1i] Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. [i#J Clin Oncol#1i] 2004; [b#22#1b]: 1389-97.
57. Tsubota K, Inoue H, Ando K [i#et al.#1i] Adenovirus-mediated gene transfer to the ocular surface epithelium. [i#Exp Eye Res#1i] 1998; [b#67#1b] 531-8.
58. Wu E, Fernandez J, Fleck SK [i#et al.#1i] A 50-kDa membrane protein mediates sialic acid-independent binding and infection of conjunctival cells by adenovirus type 37. [i#Virology#1i] 2001; [b#279#1b]: 78-89.
59. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. [i#Nature Med#1i] 2003; [b#9#1b]: 1408-12.
60. Wu E, Trauger SA, Pache L [i#et al.#1i] Membrane cofactor protein is a receptor for adenoviruses associated with epidemic keratoconjunctivitis. [i#J Virol#1i] 2004; [b#78#1b]: 3897-905.
61. Gipson IK, Argueso P. Role of mucins in the function of the corneal and conjunctival epithelia. [i#Int Rev Cytol#1i] 2003; [b#231#1b]: 1-49.
62. D'Cruz OJ, Wild RA, Medders DE [i#et al.#1i] Antigenic similarities between respiratory and reproductive tract mucins: Heterogeneity of mucin expression by human endocervix and endometrium. [i#Fertil Steril#1i] 1993; [b#60#1b]: 1011-9.
63. D'Cruz OJ, Dunn TS, Pichan P [i#et al.#1i] Antigenic cross-reactivity of human tracheal mucin with human sperm and trophoblasts correlates with the expression of mucin 8 gene messenger ribonucleic acid in reproductive tract tissues. [i#Fertil Steril#1i] 1996; [b#66#1b]: 316-26.
64. D'Cruz OJ, Wild RA. Evaluation of endometrial tissue specific complement activation in women with endometriosis. [i#Fertil Steril#1i] 1992; [b#57#1b] 787-95.
65. Bora NS, Gobleman CL, Atkinson JP [i#et al.#1i] Differential expression of the complement regulatory proteins in the human eye. [i#Invest Ophthalmol Vis Sci#1i] 1993; [b#34#1b]: 3579-84.
66. D'Cruz OJ, Haas GG Jr. The expression of the complement regulators CD46, CD55, and CD59 by human sperm does not protect them from antisperm antibody-and complement-mediated immune injury. [i#Fertil Steril#1i] 1993; [b#59#1b]; 876-84.
67. Cocuzzi E, Szczotka LB, Brodbeck WG [i#et al.#1i] Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF). [i#Clin Exp Immunol#1i] 2001; [b#123#1b]: 188-95.
68. Duke-Elder S. [i#System of Ophthalmology, Vol. VIII, Diseases of the Outer Eye, Part 1#1i]. St Louis, MO, USA: CV Mosby, 1965; 337-48.
69. Gottsch JD. Surveillance and control of epidemic keratoconjunctivitis. [i#Trans Am Ophthalmol Soc#1i] 1996; [b#94#1b]: 539-87.
70. Chodosh J, Astley RA, Butler MG [i#et al.#1i] Adenovirus keratitis: A role for Interleukin 8. [i#Invest Ophthalmol Vis Sci#1i] 2000; [b#41#1b]: 783-9.
71. Trousdale MD, Nobrega R, Wood RL [i#et al.#1i] Role of adenovirus type 5 early region in the pathogenesis of ocular disease and cell culture infection. [i#Cornea#1i] 1995; [b#14#1b]: 280-9.
72. Jones BR. The clinical features of viral keratitis and a concept of their pathogenesis. [i#Proc R Soc Med#1i] 1958; [b#51#1b]: 13-20.
73. Reefschlager J, Brwolff D, Barwolff D [i#et al.#1i] Efficiency and selectivity of (E)-5-(2-bromovinyl)-2′-deoxyuridine and some other 5-substituted 2′-deoxypyrimidine nucleosides as anti-herpes agents. [i#Antiviral Res#1i] 1982; [b#2#1b]: 41-52.
74. van der Vliet PC, Kwant MM. Role of DNA polymerase gamma in adenovirus DNA replication. Mechanism of inhibition by 2′,3′-dideoxynucleoside 5′-triphosphates. [i#Biochemistry#1i] 1981; [b#20#1b]: 2628-32.
75. Mentel R, Kinder M, Wegner U [i#et al.#1i] Inhibitory activity of 3′-fluoro-2′ deoxythymidine and related nucleoside analogues against adenoviruses in vitro. [i#Antiviral Res#1i] 1997; [b#34#1b]: 113-9.
76. Mentel R, Kurek S, Wegner U [i#et al.#1i] Inhibition of adenovirus DNA polymerase by modified nucleoside triphosphate analogs correlate with their antiviral effects on cellular level. [i#Med Microbiol Immunol#1i] 2000; [b#189#1b]; 91-5.
77. Allen LB, Boswell KH, Khwaja TA [i#et al.#1i] Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleoside, 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin). [i#J Med Chem#1i] 1978; [b#21#1b]: 742-6.
78. Naesens L, Lenaerts L, Andrei G [i#et al.#1i] Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. [i#Antimicrob Agents Chemother#1i] 2005; [b#49#1b]: 1010-6.
79. Mul YM, van Miltenburg RT, De Clercq E [i#et al.#1i] Mechanism of inhibition of adenovirus DNA replication by the acyclic nucleoside triphosphate analogue [i#(S)#1i]-HPMPApp: Influence of the adenovirus DNA binding protein. [i#Nucleic Acids Res#1i] 1989; [b#17#1b]: 8917-29.
80. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. [i#Clin Microbiol Rev#1i] 2003; [b#16#1b]: 569-96.
81. Fanourgiakis P, Georgala A, Vekemans M [i#et al.#1i] Intravesical instillation of cidofovir in the treatment of hemorrhagic cystitis caused by adenovirus type 11 in a bone marrow transplant recipient. [i#Clin Infect Dis#1i] 2005; [b#40#1b]: 199-201.
82. Ljungman P. Treatment of adenovirus infections in the immunocompromised host. [i#Eur J Clin Microbiol Infect Dis#1i] 2004; [b#23#1b]: 583-8.
83. Maslo C, Girard PM, Urban T [i#et al.#1i] Ribavirin therapy for adenovirus pneumonia in an AIDS patient. [i#Am J Respir Crit Care Med#1i] 1997; [b#156#1b]; 1263-4.
84. De Clercq E. Antiviral drugs in current clinical use. [i#J Clin Virol#1i] 2004; [b#30#1b]: 115-33.
85. Anekthananon T, Ratanasuwan W, Techasathit W [i#et al.#1i] Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: A 24-week study. [i#J Med Assoc Thailand#1i] 2004; [b#87#1b]: 760-7.
86. Laurent C, Kouanfack C, Koulla-Shiro S [i#et al.#1i] Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: Open-label multicentre trial. [i#Lancet#1i] 2004; [b#364#1b]: 29-34.
87. Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. [i#J Biol Chem#1i] 1989; [b#264#1b]; 6127-33.
88. McIntee EJ, Remmel RP, Schinazi RF [i#et al.#1i] Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs. [i#J Med Chem#1i] 1997; [b#40#1b]: 3323-31.
89. McGuigan C, Cahard D, Sheeka M [i#et al.#1i] Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. [i#J Med Chem#1i] 1996; [b#39#1b]: 1748-53.
90. D'Cruz OJ, Venkatachalam TK, Uckun FM. Thymidine kinase-independent intracellular delivery of bioactive nucleotides by aryl phosphate derivatives of bromo-methoxy zidovudine (compounds WHI-05 and WHI-07) in normal human female genital tract epithelial cells and sperm. [i#Biol Reprod#1i] 2001; [b#64#1b]: 51-9.
91. Vig R, Venkatachalam TK, Uckun FM. d4T-5′- i p#1i]-bromophenyl methoxya laninyl phosphate] as a potent and non-toxic anti-human immunodeficiency virus agent. [i#Antivir Chem Chemother#1i] 1998; [b#9#1b]: 445-8.
92. Uckun FM, Pendergrass S, Qazi S [i#et al.#1i] Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus. [i#Eur J Med Chem#1i] 2004; [b#39#1b]: 225-34.
93. Uckun FM, Pendergrass S, Qazi S [i#et al.#1i] In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates. [i#Arzneimittelforschung#1i] 2004; [b#54#1b]: 69-77.
94. Uckun FM, Pendergrass S, Venkatachalam TK [i#et al.#1i] Stampidine is a potent inhibitor of zidovudine and NRTI-resistant primary clinical HIV-1 isolates with thymidine analog mutations. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b], 3613-6.
95. Uckun FM, Samuel P, Qazi S [i#et al.#1i] Effects of aryl substituents on the anti-HIV activity of the arylphosphoramidate derivatives of stavudine. [i#Antivir Chem Chemother#1i] 2002; [b#13#1b]: 197-203.
96. Uckun FM, Qazi S, Pendergrass S [i#et al.#1i] In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5′-([i#p#1i]-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice. [i#Antimicrob Agents Chemother#1i] 2002; [b#46#1b]: 3428-36.
97. Uckun FM, Chen CL, Samuel P [i#et al.#1i] In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. [i#Antimicrob Agents Chemother#1i] 2003; [b#47#1b]: 1233-40.
98. Chen CL, Yu G, Venkatachalam TK [i#et al.#1i] Metabolism of stavudine-5′- i p#1i]-bromophenyl methoxyalaninyl phosphate], stampidin e, in mice, dogs, and cats. [i#Drug Metab Dispos#1i] 2002; [b#30#1b]: 1523-31.
99. Uckun FM, Chen CL, Lisowski E [i#et al.#1i] Toxicity and pharmacokinetics of stampidine in mice and rats. [i#Arzneimittelforschung#1i] 2003; [b#53#1b] 357-67.
100. Qazi S, Samuel NK, Venkatachalam TK [i#et al.#1i] Evaluating dissolution profiles of an anti-HIV agent using ANOVA and non-linear regression models in JMP software. [i#Int J Pharm#1i] 2003; [b#252#1b]: 27-39.
101. Venkatachalam TK, Samuel P, Li G [i#et al.#1i] Lipase-mediated stereoselective hydrolysis of stampidine and other phosphoramidate derivatives of stavudine. [i#Bioorg Med Chem#1i] 2004; [b#12#1b]: 3371-81.
102. Venkatachalam TK, Yu G, Samuel P [i#et al.#1i] A comparative study of the hydrolysis pathways of substituted aryl phosphoramidate vs aryl thio-phosphoramidate derivatives of stavudine. [i#Eur J Med Chem#1i] 2004; [b#39#1b]: 665-83.
103. Venkatachalam TK, Samuel P, Uckun FM. Stereochemical influence on lipase-mediated hydrolysis and biological activity of stampidine and other stavudine phosphoramidates. [i#Bioorg Med Chem#1i] 2005; [b#13#1b]: 1763-73.
104. Venkatachalam TK, Samuel P, Uckun FM. Enzymatic hydrolysis of stampidine and other stavudine phosphoramidates in the presence of mammalian proteases. [i#Bioorg Med Chem#1i] 2005; [b#13#1b]: 2651-5.
105. D'Cruz OJ, Uckun FM. Stampidine is a nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide [i#Fertil Steril#1i] 2003; [b#81#1b]: 831-41.
106. D'Cruz OJ, Samuel P, Waurzyniak B [i#et al. In vivo#1i] evaluation of a gel formulation of stampidine, a novel nonspermicidal broad-spectrum anti-HIV microbicide. [i#Am J Drug Deliv#1i] 2003; [b#1#1b]: 275-85.
107. D'Cruz OJ, Samuel P, Waurzyniak B [i#et al.#1i] Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel non-spermicidal broad-spectrum anti-HIV microbicide. [i#Biol Reprod#1i] 2003; [b#69#1b]: 1843-51.
108. D'Cruz OJ, Samuel P, Uckun FM. Conceival, a novel non-contraceptive vaginal vehicle for lipophilic microbicides. [i#AAAPS PharmSciTech#1i] 2005; [b#6#1b]: In press. http://www.aapspharmscitech.org/prepub/ prepub.asp (15 April 2005, date last accessed).
109. Venkatachalam TK, Tai HL, Vig R [i#et al.#1i] Enhancing effects of a mono-bromo substitution at the [i#para#1i] position of the phenyl moiety on the metabolism and anti-HIV activity of D4T-phenyl methoxyalaninyl phosphate derivatives. [i#Bioorg Med Chem Lett#1i] 1998; [b#8#1b]: 3121-6.
110. Saviola JF, Hilmantel G, Rosenthal AR. The U.S. Food and Drug Administration's role in contact lens development and safety. [i#Eye Contact Lens#1i] 2003; [b#29#1b]: S160-5.
111. Uckun FM, Tai HL, D'Cruz OJ. Antileukemic activity and cellular metabolism of the aryl phosphate derivative of bromo-methoxy zidovudine (compound WHI-07). [i#Arzneimittelforschung#1i] 2005; [b#55#1b]: 50-65.